BODMER; MARK WILLIAM
Patent Applications and Registrations
Patent applications and USPTO patent grants for BODMER; MARK WILLIAM.The latest application filed is for "a composition comprising a notch ligand and an allergenb or allergen bystander antigen".
- BODMER; MARK WILLIAM - CAMBRIDGE GB
- Bodmer; Mark William - South Hinksey GB
- Bodmer, Mark William - Oxford GB
- Bodmer; Mark William - Oxfordshire GB
- Bodmer; Mark William - Slough Berkshire GB
- Bodmer; Mark William - Henley-On-Thames GB
| Patent | Date |
|---|---|
| A Composition Comprising A Notch Ligand And An Allergenb Or Allergen Bystander Antigen App 20100303867 - BODMER; MARK WILLIAM ; et al. | 2010-12-02 |
| Interleukin-5 specific recombinant antibodies Grant RE39,548 - Bodmer , et al. April 3, 2 | 2007-04-03 |
| Treatment of allergic diseases using a modulator of the Notch signaling pathway App 20060205823 - Bodmer; Mark William ; et al. | 2006-09-14 |
| Conjugate of notch signalling pathway modulators and their use in medical treatment App 20060002924 - Bodmer; Mark William ; et al. | 2006-01-05 |
| Modulators of the Notch signalling pathway and uses thereof in medical treatment App 20050220886 - Bodmer, Mark William ; et al. | 2005-10-06 |
| Medical treatment App 20050137130 - Bodmer, Mark William ; et al. | 2005-06-23 |
| Method for detecting modulators of Notch signalling App 20050059093 - Bodmer, Mark William ; et al. | 2005-03-17 |
| Modulators of Notch signalling for use in immunotherapy App 20050025751 - Bodmer, Mark William ; et al. | 2005-02-03 |
| Medical treatment App 20050026831 - Bodmer, Mark William ; et al. | 2005-02-03 |
| Conjugates for the modulation of immune responses App 20040213797 - Bodmer, Mark William ; et al. | 2004-10-28 |
| Interleukin-5 specific recombinant antibodies Grant 6,734,286 - Bodmer , et al. May 11, 2 | 2004-05-11 |
| Recombinant antibodies specific for TNF-alpha App 20030199679 - Adair, John Robert ; et al. | 2003-10-23 |
| Interleukin-5 specific recombinant antibodies App 20020042089 - Bodmer, Mark William ; et al. | 2002-04-11 |
| Nucleic acids encoding interleukin-5 specific recombinant antibodies Grant 6,316,227 - Bodmer , et al. November 13, 2 | 2001-11-13 |
| Pharmaceutical product for the treatment of sepsis Grant 6,315,999 - Sadoff , et al. November 13, 2 | 2001-11-13 |
| Humanized antibodies Grant 6,180,377 - Morgan , et al. January 30, 2 | 2001-01-30 |
| Use of estrone derivatives as steroid sulphatase inhibitors Grant 6,013,642 - Foulkes , et al. January 11, 2 | 2000-01-11 |
| Interleukin-5 specific recombinant antibodies Grant 5,998,586 - Bodmer , et al. December 7, 1 | 1999-12-07 |
| Recombinant antibodies specific for TNF.alpha. Grant 5,994,510 - Adair , et al. November 30, 1 | 1999-11-30 |
| Method for producing Fv fragments in eukaryotic cells Grant 5,965,405 - Winter , et al. October 12, 1 | 1999-10-12 |
| Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor Grant 5,958,413 - Anagnostopulos , et al. September 28, 1 | 1999-09-28 |
| CDR grafted anti-CEA antibodies and their production Grant 5,877,293 - Adair , et al. March 2, 1 | 1999-03-02 |
| Recombinant antibody Grant 5,677,425 - Bodmer , et al. Oc | 1997-10-14 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 